See more : Australian Oilseeds Holdings Limited Warrant (COOTW) Income Statement Analysis – Financial Results
Complete financial analysis of Imunon, Inc. (CLSN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imunon, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shanghai QiFan Cable Co., Ltd (605222.SS) Income Statement Analysis – Financial Results
- Waste Connections, Inc. (WCN.TO) Income Statement Analysis – Financial Results
- ICBS, Ltd. (ICBT) Income Statement Analysis – Financial Results
- Aditya Birla Fashion and Retail Limited (ABFRL.BO) Income Statement Analysis – Financial Results
- Rurelec PLC (RUR.L) Income Statement Analysis – Financial Results
Imunon, Inc. (CLSN)
About Imunon, Inc.
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 | 2.00M | 0.00 | 0.00 | 2.50M | 0.00 | 11.25M | 12.32M | 2.51M | 0.00 | 0.00 | 0.00 | 3.42K | 100.00K | 174.18K | 121.26K | 74.01K |
| Cost of Revenue | 720.01K | 731.63K | 702.92K | 11.34M | 13.07M | 11.07M | 13.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.67M | 8.11M | 2.10M | 0.00 | 0.00 | 0.00 | -39.23K | 0.00 | 136.50K | 46.73K | 64.41K |
| Gross Profit | -720.01K | -231.63K | -202.92K | -10.84M | -12.57M | -10.57M | -12.58M | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 | 2.00M | 0.00 | 0.00 | 2.50M | 0.00 | 4.58M | 4.21M | 405.34K | 0.00 | 0.00 | 0.00 | 42.65K | 100.00K | 37.68K | 74.52K | 9.60K |
| Gross Profit Ratio | 0.00% | -46.33% | -40.58% | -2,168.96% | -2,513.06% | -2,113.10% | -2,515.74% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 40.72% | 34.15% | 16.17% | 0.00% | 0.00% | 0.00% | 1,247.13% | 100.00% | 21.63% | 61.46% | 12.97% |
| Research & Development | 11.29M | 11.73M | 10.62M | 11.34M | 13.07M | 11.87M | 13.08M | 14.62M | 14.66M | 14.97M | 9.36M | 15.77M | 19.86M | 14.71M | 13.68M | 12.01M | 8.23M | 9.35M | 10.08M | 11.53M | 8.18M | 5.00M | 4.08M | 2.24M | 1.00M | 1.53M | 185.97K | 94.01K |
| General & Administrative | 9.74M | 13.69M | 10.89M | 7.64M | 8.00M | 9.70M | 5.89M | 6.53M | 6.69M | 8.86M | 6.55M | 6.37M | 0.00 | 4.92M | 3.33M | 2.04M | 5.35M | 3.72M | 3.41M | 0.00 | 0.00 | 4.83M | 3.21M | 2.66M | 1.40M | 2.52M | 2.28M | 1.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 390.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.74M | 13.69M | 10.89M | 7.64M | 8.00M | 9.70M | 5.89M | 6.53M | 6.69M | 8.86M | 6.55M | 6.37M | 5.15M | 4.92M | 3.33M | 2.04M | 5.35M | 3.72M | 3.41M | 3.47M | 5.13M | 4.83M | 3.21M | 2.66M | 1.40M | 2.52M | 2.28M | 1.34M |
| Other Expenses | 0.00 | 5.40M | 1.62M | -1.30M | 3.19M | 3.63M | 651.97K | 733.00K | -259.45K | 265.89K | -2.53K | -1.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.03M | 25.42M | 21.51M | 18.99M | 21.07M | 21.57M | 18.97M | 21.15M | 21.35M | 23.83M | 15.91M | 22.14M | 25.02M | 19.64M | 17.01M | 14.05M | 13.59M | 14.08M | 13.49M | 15.00M | 13.30M | 9.84M | 7.29M | 4.94M | 2.40M | 4.05M | 2.47M | 1.43M |
| Cost & Expenses | 21.03M | 25.42M | 21.51M | 18.99M | 21.07M | 21.57M | 18.97M | 21.15M | 21.35M | 23.83M | 15.91M | 22.14M | 25.02M | 19.64M | 17.01M | 14.05M | 13.59M | 20.75M | 21.60M | 17.11M | 13.30M | 9.84M | 7.29M | 4.90M | 2.40M | 4.19M | 2.52M | 1.50M |
| Interest Income | 960.55K | 502.58K | 18.15K | 66.55K | 442.99K | 331.78K | 26.04K | 31.26K | 186.32K | 1.02M | 748.95K | 0.00 | 174.06K | 32.29K | 46.16K | 221.71K | 0.00 | 636.56K | 299.25K | 0.00 | 30.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 4.57M | 557.00K | 1.29M | 1.39M | 712.03K | 91.76K | 693.00K | 1.36M | 1.33M | 915.24K | 307.00K | 501.86K | 31.52K | 94.92K | 141.61K | 49.42M | 1.10M | 179.59K | 0.00 | -13.27M | -9.75M | -6.92M | 0.00 | 0.00 | 199.35K | 0.00 | 85.51K |
| Depreciation & Amortization | 720.01K | 731.63K | 702.92K | 741.52K | 721.67K | 356.86K | 553.01K | 1.03M | 424.97K | 369.33K | 339.23K | 281.49K | 176.86K | 172.98K | 109.65K | 69.47K | -39.11K | -341.29K | -321.39K | -275.68K | 100.53K | 82.44K | 68.85K | 39.48K | -100.00K | 24.29K | 24.17K | 18.55K |
| EBITDA | -19.88M | -31.71M | -20.88M | -21.30M | -16.55M | -21.23M | -19.76M | -20.30M | -20.67M | -23.79M | -6.99M | -25.92M | -22.54M | -18.61M | -15.80M | -11.58M | -13.13M | -9.84M | -9.50M | -14.78M | -13.20M | -9.79M | -7.26M | -4.86M | -2.40M | -3.99M | -2.37M | -1.40M |
| EBITDA Ratio | 0.00% | -3,905.20% | -3,877.00% | -3,795.72% | -3,242.17% | -3,349.10% | -3,447.48% | -3,983.40% | -4,098.99% | -4,335.91% | -2,865.17% | 0.00% | -1,133.39% | 0.00% | 0.00% | -463.01% | 0.00% | -94.55% | -77.14% | -589.83% | 0.00% | 0.00% | 0.00% | -142,016.75% | -2,300.00% | -2,296.79% | -1,960.88% | -1,936.39% |
| Operating Income | -21.03M | -24.92M | -21.01M | -18.49M | -20.57M | -21.07M | -18.47M | -20.65M | -20.85M | -24.72M | -15.41M | -22.14M | -23.02M | -19.64M | -17.01M | -11.55M | -13.59M | -8.49M | -9.28M | -14.60M | -13.30M | -9.84M | -7.29M | -4.90M | -2.30M | -4.01M | -2.39M | -1.42M |
| Operating Income Ratio | 0.00% | -4,984.40% | -4,201.40% | -3,697.28% | -4,113.09% | -4,213.01% | -3,693.69% | -4,130.00% | -4,169.36% | -4,943.04% | -3,082.30% | 0.00% | -1,150.94% | 0.00% | 0.00% | -461.98% | 0.00% | -75.43% | -75.32% | -582.51% | 0.00% | 0.00% | 0.00% | -143,171.08% | -2,300.00% | -2,303.92% | -1,974.89% | -1,922.52% |
| Total Other Income/Expenses | 235.07K | -12.54M | -1.15M | -4.84M | 1.90M | -1.24M | -1.93M | -1.40M | -1.61M | -779.08K | 7.16M | -4.43M | -203.91K | 818.99K | 1.01M | -236.80K | -483.23K | 902.40K | -96.89K | 613.90K | 30.38K | 86.61K | 363.65K | 349.24K | -100.00K | -187.48K | -657.19K | -510.69K |
| Income Before Tax | -20.80M | -37.47M | -22.15M | -23.33M | -18.67M | -22.30M | -20.40M | -22.05M | -22.46M | -25.49M | -8.25M | -26.57M | -23.22M | -18.82M | -16.00M | -11.79M | -14.07M | -7.58M | -8.69M | -13.99M | -13.27M | -9.75M | -6.92M | -4.55M | -2.40M | -4.20M | -3.05M | -1.93M |
| Income Before Tax Ratio | 0.00% | -7,493.00% | -4,430.60% | -4,665.88% | -3,733.60% | -4,460.49% | -4,080.44% | -4,410.80% | -4,492.22% | -5,098.85% | -1,650.27% | 0.00% | -1,161.13% | 0.00% | 0.00% | -471.45% | 0.00% | -67.41% | -70.50% | -558.01% | 0.00% | 0.00% | 0.00% | -132,959.50% | -2,400.00% | -2,411.55% | -2,516.88% | -2,612.59% |
| Income Tax Expense | -1.28M | -1.57M | -1.38M | -1.85M | -1.82M | -10.42M | 1.93M | 1.40M | 1.61M | 779.08K | 1.00 | 4.43M | 203.91K | -818.99K | -806.00K | 236.80K | -49.42M | -1.91M | 8.69M | -613.90K | 13.27M | 9.75M | 6.92M | 4.55M | 2.40M | 187.48K | 657.19K | 510.69K |
| Net Income | -19.51M | -35.90M | -20.77M | -21.48M | -16.85M | -11.88M | -20.40M | -22.05M | -22.46M | -25.49M | -8.25M | -26.57M | -23.22M | -18.82M | -15.19M | -11.79M | 35.35M | -7.58M | -8.69M | -13.99M | -13.27M | -9.75M | -6.92M | -4.55M | -2.40M | -4.20M | -3.05M | -1.93M |
| Net Income Ratio | 0.00% | -7,179.60% | -4,153.80% | -4,296.71% | -3,370.31% | -2,376.67% | -4,080.44% | -4,410.80% | -4,492.22% | -5,098.85% | -1,650.27% | 0.00% | -1,161.13% | 0.00% | 0.00% | -471.45% | 0.00% | -67.41% | -70.50% | -558.01% | 0.00% | 0.00% | 0.00% | -132,959.50% | -2,400.00% | -2,411.55% | -2,516.88% | -2,612.59% |
| EPS | -2.16 | -5.03 | -3.60 | -10.08 | -11.58 | -10.14 | -40.12 | -178.43 | -216.24 | -289.83 | -127.97 | -721.68 | -1.05K | -1.44K | -1.35K | -1.10K | 3.11K | -668.10 | -765.29 | -1.25K | -1.66K | -1.58K | -1.36K | -1.09K | -741.20 | -105.01 | -1.52K | -1.09K |
| EPS Diluted | -2.16 | -5.03 | -3.60 | -10.08 | -11.58 | -10.14 | -40.12 | -178.42 | -216.24 | -289.83 | -127.97 | -721.68 | -1.05K | -1.44K | -1.35K | -1.10K | 2.90K | -668.10 | -760.54 | -1.25K | -1.66K | -1.58K | -1.36K | -1.09K | -741.20 | -193.97 | -1.52K | -1.09K |
| Weighted Avg Shares Out | 9.05M | 7.14M | 5.77M | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K | 22.14K | 13.10K | 11.28K | 10.74K | 11.36K | 11.35K | 11.35K | 11.20K | 8.02K | 6.16K | 5.10K | 4.19K | 3.24K | 40.00K | 2.00K | 1.78K |
| Weighted Avg Shares Out (Dil) | 9.05M | 7.14M | 5.77M | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K | 22.14K | 13.10K | 11.28K | 10.74K | 12.18K | 11.35K | 11.42K | 11.20K | 8.02K | 6.16K | 5.10K | 4.19K | 3.24K | 21.66K | 2.00K | 1.78K |
Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 with In-Process Vaccine Candidate
Preclinical results d emonstrate safe and efficient immune response with v accine development showing promise of neutralizing activity for a range of variants
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
LAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced the closing of its previously announced registered direct offering with certain institutional investors to purchase...
Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit
Celsion Corporation 's GEN-1 IL-12 Program in Ad vanced Ovarian Cancer to be Featured in Poster Presentation
Celsion Corporation (CLSN) CEO Michael Tardugno on Q3 2021 Results - Earnings Call Transcript
Celsion Corporation (CLSN) CEO Michael Tardugno on Q3 2021 Results - Earnings Call Transcript
Celsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update
Balance Sheet Supports Focus o n Immuno-Oncology and Next-Generation Vaccine Initiative
Celsion Corporation to Hold Third Quarter 2021 Financial Results and Business Update Conference Call on Monday, November 15, 2021
LAWRENCEVILLE, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, November 15, 2021 to discuss...
Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses
Application A pproval Will Further Extend Current Operating Runway to Over Three Years
Celsion Corporation's GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit
Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions
Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress
Chief Science Officer Dr. Khursheed Anwer to D eliver V irtual P resentation Monday, October 18 at 7:30 a.m. Eastern Time
CLSN Stock: Why It Increased This Week
The stock price of Celsion Corporation (NASDAQ: CLSN) increased from $0.88 on Thursday to about $0.95-$1 today. This is why it happened.
Source: https://incomestatements.info
Category: Stock Reports